The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Multicenter sequential phase II study of flavopiridol plus oxaliplatin (alvocidib) with or without 5-FU and leucovorin (LV) for patients (pts) with refractory germ cell tumors (GCT) including late relapse (LR).
Darren Richard Feldman
No relevant relationships to disclose
Walter Michael Stadler
No relevant relationships to disclose
Leonard Joseph Appleman
No relevant relationships to disclose
David I. Quinn
No relevant relationships to disclose
Brian Addis Costello
No relevant relationships to disclose
Gary K. Schwartz
No relevant relationships to disclose
Victor E. Reuter
No relevant relationships to disclose
Kaitlyn Woo
No relevant relationships to disclose
Sujata Patil
No relevant relationships to disclose
Anne Fusco
No relevant relationships to disclose
Sloane C. Smith
No relevant relationships to disclose
Jeremie Carlson
No relevant relationships to disclose
George J. Bosl
No relevant relationships to disclose
Robert John Motzer
No relevant relationships to disclose